Evidence map›Paper›PMID 33615067›Full record

ArticleKidney international reports2021

Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort.

Suceena Alexander, Santosh Varughese, Rajanbabu Franklin, Sanjeet Roy, Grace Rebekah, Vinoi George David, Anjali Mohapatra, Anna T Valson, Shibu Jacob, Pradeep Mathew Koshy and 5 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. An Unusual Presentation of IgA Vasculitis and IgA Nephropathy: A Case Report.Journal of community hospital internal medicine perspectives · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Suceena AlexanderDepartment of Nephrology, Christian Medical College, Vellore, India.
Santosh VarugheseDepartment of Nephrology, Christian Medical College, Vellore, India.
Rajanbabu FranklinDepartment of Nephrology, Christian Medical College, Vellore, India.
Sanjeet RoyDepartment of General Pathology, Christian Medical College, Vellore, India.
Grace RebekahDepartment of Biostatistics, Christian Medical College, Vellore, India.
Vinoi George DavidDepartment of Nephrology, Christian Medical College, Vellore, India.
Anjali MohapatraDepartment of Nephrology, Christian Medical College, Vellore, India.
Anna T ValsonDepartment of Nephrology, Christian Medical College, Vellore, India.
Shibu JacobDepartment of Nephrology, Christian Medical College, Vellore, India.
Pradeep Mathew KoshyDepartment of Nephrology, Christian Medical College, Vellore, India.
Gautham RajanDepartment of Nephrology, Christian Medical College, Vellore, India.
Mohamed R DahaUniversity Medical Center Groningen, the Netherlands.
John FeehallyUniversity of Leicester College of Medicine Biological Sciences and Psychology, UK.
Jonathan BarrattUniversity of Leicester College of Medicine Biological Sciences and Psychology, UK.
George T JohnDepartment of Nephrology, Christian Medical College, Vellore, India.
Christian Medical College & Hospital · INUniversity of Leicester · GBUniversity Medical Center Groningen · NL

Funding

DBT-Wellcome Trust India Alliance IA/CPHE/14/1/501501Wellcome Trust
6 · The paper itself

Abstract

introductionGlomerular Research And Clinical Experiments-IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgAN cohort with protocolized follow-up and extensive biosample collection. Here we report the baseline clinical, biochemical, and histopathologic characteristics of GRACE IgANI and calculate baseline risk of progression for the cohort.

methods201 incident adults with kidney biopsy-proven primary IgAN were recruited into GRACE-IgANI between March 2015 and September 2017. As of April 30, 2020, the cohort had completed a median follow-up of 30 months (interquartile range [IQR] 16-39).

resultsThe commonest clinical presentation in GRACE IgANI was hypertension, with or without proteinuria, and nephrotic-range proteinuria was present in 34%, despite <10 months of lead time to kidney biopsy. The GRACE-IgANI kidney biopsy data demonstrated a disproportionate absence of active glomerular lesions and overrepresentation of segmental sclerosing lesions and tubulointerstitial fibrosis at presentation, often coexistent with relatively well-preserved estimated glomerular filtration rate (eGFR) and low levels of proteinuria, especially in males. Baseline risk of progression was calculated for each evaluable patient using 2 different risk prediction tools. The median 5-year absolute risk of end-stage kidney disease (ESKD) was 19.8% (IQR 2.7-57.4) and median 5-year risk of progression to the combined endpoint of 50% decline in eGFR or ESKD was 35.5% using the 2 tools.

conclusionsThe predicted risk of progression in this cohort was considerable. Over the next 5 years, we will dissect the pathogenic pathways that underlie this severe South Asian IgAN phenotype.

Indexed as

chronic kidney diseaseglomerulonephritisIgA nephropathyimmune-mediated kidney diseaserenal risk scoreSouth Asia

Identifiers

PMID33615067
PMCPMC7879115
OpenAlexW3111740813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.